safinamide has been researched along with selegiline in 25 studies
| Studies (safinamide) | Trials (safinamide) | Recent Studies (post-2010) (safinamide) | Studies (selegiline) | Trials (selegiline) | Recent Studies (post-2010) (selegiline) |
|---|---|---|---|---|---|
| 199 | 29 | 159 | 2,575 | 319 | 394 |
| Protein | Taxonomy | safinamide (IC50) | selegiline (IC50) |
|---|---|---|---|
| Cholinesterase | Homo sapiens (human) | 0.0055 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.0039 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 1.798 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.376 | |
| Amine oxidase [flavin-containing] B | Rattus norvegicus (Norway rat) | 0.2127 | |
| Amine oxidase [flavin-containing] A | Rattus norvegicus (Norway rat) | 0.9046 | |
| Amine oxidase [flavin-containing] A | Homo sapiens (human) | 1.4408 | |
| Adenosine receptor A1 | Rattus norvegicus (Norway rat) | 0.0067 | |
| Amine oxidase [flavin-containing] B | Homo sapiens (human) | 0.1001 | |
| Type-1 angiotensin II receptor | Sus scrofa (pig) | 0.048 | |
| Alpha-synuclein | Homo sapiens (human) | 0.27 | |
| Amine oxidase [flavin-containing] B | Bos taurus (cattle) | 1 | |
| Sigma intracellular receptor 2 | Rattus norvegicus (Norway rat) | 0.017 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (4.00) | 29.6817 |
| 2010's | 16 (64.00) | 24.3611 |
| 2020's | 8 (32.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gütschow, M; Heer, J; Hinz, S; Küppers, P; Müller, CE; Schlenk, M; Stössel, A | 1 |
| Akkari, R; Borrmann, T; Brunschweiger, A; Drabczyńska, A; Hockemeyer, J; Kieć-Kononowicz, K; Koch, P; Köse, M; Küppers, P; Müller, CE; Radjainia, H; Schlenk, M | 1 |
| Almos, T; Edmondson, DE; Massari, ME; Rojas, RJ; Scott, R | 1 |
| Cho, NC; Choi, JW; Han, G; Jang, BK; Ju, EJ; Kim, DJ; Lee, YS; Pae, AN; Park, JH; Park, KD; Yeon, SK | 1 |
| Mostert, S; Petzer, A; Petzer, JP | 2 |
| Kim, YS; Lee, J; Lee, Y; Park, SJ; Suh, YG | 1 |
| Alcaro, S; Bagetta, D; Borges, F; Fonseca, A; Matos, MJ; Ortuso, F; Reis, J; Silva, T; Uriarte, E | 1 |
| Bahn, YS; Choi, JW; Han, G; Jang, BK; Kim, HJ; Kim, S; Lee, YR; Lee, YS; Pae, AN; Park, JH; Park, KD; Shin, SJ; Yeon, SK | 1 |
| Buchwalder, C; Devineau, A; Dullaghan, EM; Gealageas, R; Goebeler, V; Grierson, DS; Heller, M; Kim, CMJ; Putnins, EE; So, PPL; Surendradoss, J | 1 |
| Alcaro, S; Bagetta, D; Borges, F; Cagide, F; Oliveira, PJ; Ortuso, F; Pérez, C; Reis, J; Rodríguez-Franco, MI; Teixeira, J; Uriarte, E; Valencia, ME | 1 |
| Bajda, M; Cichoń, U; Doroz-Płonka, A; Kaleta, M; Karcz, T; Kieć-Kononowicz, K; Kuder, K; Olejarz-Maciej, A; Siwek, A; Łażewska, D | 1 |
| Antonov, L; Atanasov, AG; Hristova, S; Stammler, HG; Tzvetkov, NT | 1 |
| Cheng, K; Duan, Y; Han, J; Huang, X; Kong, H; Li, S; Liao, C; Lv, X; Tian, Y; Xie, Z | 1 |
| Antonov, L; Atanasov, AG; Balacheva, AA; Faraone, I; Gastreich, M; Georgieva, MG; Hristova, S; Milella, L; Russo, D; Stammler, HG; Tzvetkov, NT | 1 |
| Borges, F; Chavarria, D; Fernandes, C; Gil-Martins, E; Oliveira, PJ; Remião, F; Silva, C; Silva, R; Silva, T; Silva, V; Soares, P | 1 |
| Chen, KZ; Hao, GF; Jin, CF; Wang, ZZ; Xu, TF | 1 |
| Acar Çevik, U; Kaplancıklı, ZA; Kaya Çavuşoğlu, B; Levent, S; Osmaniye, D; Özkay, Y; Sağlık, BN | 1 |
| Chen, JJ; Fernandez, HH | 1 |
| Alborghetti, M; Nicoletti, F | 1 |
| Parambi, DGT | 1 |
| Alborghetti, M; Bianchini, E; Galli, S; Pontieri, FE; Rinaldi, D; Sforza, M | 1 |
| Bovenzi, R; Candelise, N; Ferri, A; Grillo, P; Mercuri, NB; Schirinzi, T; Simonetta, C; Valle, C; Zenuni, H | 1 |
| Cai, G; Cai, H; Cui, Y; Feng, T; Lin, F; Su, D; Yan, R | 1 |
| Asano, H; Hatabu, A; Ikeda, K; Takagi, T; Tian, YS; Ueda, M | 1 |
5 review(s) available for safinamide and selegiline
| Article | Year |
|---|---|
Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dopamine Agonists; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 2007 |
Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson's Disease: From Bench to Bedside.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dopamine Agents; Humans; Indans; Levodopa; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 2019 |
Treatment of Parkinson's Disease by MAO-B Inhibitors, New Therapies and Future Challenges - A Mini-Review.
Topics: Alanine; Benzylamines; Biomarkers; Clinical Trials as Topic; Functional Neuroimaging; Genetic Therapy; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nanoparticles; Neuroprotective Agents; Parkinson Disease; Selegiline; Transplantation | 2020 |
Monoamine-oxidase Type B Inhibitors and Cognitive Functions in Parkinson's Disease: Beyond the Primary Mechanism of Action.
Topics: Antiparkinson Agents; Cognition; Dopamine; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Quality of Life; Selegiline | 2023 |
Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled
Topics: Antiparkinson Agents; Bayes Theorem; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Network Meta-Analysis; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline; Zonisamide | 2023 |
20 other study(ies) available for safinamide and selegiline
| Article | Year |
|---|---|
Dual targeting of adenosine A(2A) receptors and monoamine oxidase B by 4H-3,1-benzothiazin-4-ones.
Topics: Adenosine A2 Receptor Antagonists; Animals; Benzothiadiazines; Brain; CHO Cells; Cricetinae; Cricetulus; Cyclic AMP; Humans; In Vitro Techniques; Isoenzymes; Liver; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Phenylbutyrates; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Stereoisomerism; Structure-Activity Relationship; Thiazines | 2013 |
1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases.
Topics: Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Caffeine; CHO Cells; Cricetulus; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurodegenerative Diseases; Purinergic P1 Receptor Antagonists; Purines; Xanthines | 2013 |
Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques.
Topics: Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Small Molecule Libraries; Thermodynamics | 2015 |
Synthesis of a series of unsaturated ketone derivatives as selective and reversible monoamine oxidase inhibitors.
Topics: Binding Sites; Free Radical Scavengers; Humans; Hydrogen Peroxide; Ketones; Kinetics; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Protein Binding; Protein Structure, Tertiary; Structure-Activity Relationship | 2015 |
Inhibition of monoamine oxidase by benzoxathiolone analogues.
Topics: Benzoxazoles; Humans; Inhibitory Concentration 50; Kinetics; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Protein Binding; Protein Isoforms; Structure-Activity Relationship | 2016 |
Discovery of highly selective and potent monoamine oxidase B inhibitors: Contribution of additional phenyl rings introduced into 2-aryl-1,3,4-oxadiazin-5(6H)-one.
Topics: Benzene Derivatives; Binding Sites; Blood-Brain Barrier; Drug Discovery; Humans; Inhibitory Concentration 50; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Oxadiazoles; Sensitivity and Specificity | 2017 |
The evaluation of 1,4-benzoquinones as inhibitors of human monoamine oxidase.
Topics: Benzoquinones; Dose-Response Relationship, Drug; Humans; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship | 2017 |
Coumarin versus Chromone Monoamine Oxidase B Inhibitors: Quo Vadis?
Topics: Alanine; Benzylamines; Chromones; Clorgyline; Coumarins; Humans; Indans; Kinetics; Ligands; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Selegiline; Structure-Activity Relationship | 2017 |
Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B inhibitors toward Parkinson's disease therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzene Derivatives; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Male; Mice; Mice, Inbred C57BL; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Structure-Activity Relationship | 2018 |
Development of Novel Monoamine Oxidase-B (MAO-B) Inhibitors with Reduced Blood-Brain Barrier Permeability for the Potential Management of Noncentral Nervous System (CNS) Diseases.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood-Brain Barrier; Dogs; Drug Development; Humans; Madin Darby Canine Kidney Cells; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nervous System Diseases | 2018 |
Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors.
Topics: Alzheimer Disease; Blood-Brain Barrier; Cholinesterase Inhibitors; Cholinesterases; Chromones; Drug Design; Hep G2 Cells; Humans; Ligands; Molecular Docking Simulation; Molecular Targeted Therapy; Monoamine Oxidase; Monoamine Oxidase Inhibitors | 2018 |
4-tert-Pentylphenoxyalkyl derivatives - Histamine H
Topics: Binding Sites; Catalytic Domain; Humans; Inhibitory Concentration 50; Kinetics; Ligands; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Phenols; Receptors, Histamine H3; Structure-Activity Relationship | 2018 |
(Pyrrolo-pyridin-5-yl)benzamides: BBB permeable monoamine oxidase B inhibitors with neuroprotective effect on cortical neurons.
Topics: Benzamides; Blood-Brain Barrier; Cerebral Cortex; Models, Neurological; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurons; Neuroprotective Agents; Permeability; Structure-Activity Relationship | 2019 |
Design, synthesis and biological evaluation of novel human monoamine oxidase B inhibitors based on a fragment in an X-ray crystal structure.
Topics: Binding Sites; Catalytic Domain; Crystallography, X-Ray; Drug Design; Humans; Isatin; Molecular Dynamics Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Protein Isoforms; Structure-Activity Relationship | 2019 |
Carboxamides vs. methanimines: Crystal structures, binding interactions, photophysical studies, and biological evaluation of (indazole-5-yl)methanimines as monoamine oxidase B and acetylcholinesterase inhibitors.
Topics: Acetylcholinesterase; Amides; Cell Proliferation; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Hep G2 Cells; Humans; Imines; Models, Molecular; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship; Tumor Cells, Cultured | 2019 |
Design of novel monoamine oxidase-B inhibitors based on piperine scaffold: Structure-activity-toxicity, drug-likeness and efflux transport studies.
Topics: Alkaloids; Benzodioxoles; Caco-2 Cells; Cell Differentiation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Humans; Ligands; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Oxidative Stress; Piperidines; Polyunsaturated Alkamides; Structure-Activity Relationship; Tumor Cells, Cultured | 2020 |
Computational Fragment-Based Design Facilitates Discovery of Potent and Selective Monoamine Oxidase-B (MAO-B) Inhibitor.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alanine; Amides; Animals; Benzylamines; Binding Sites; Dopaminergic Neurons; Drug Design; Humans; Male; Mice, Inbred ICR; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Protein Binding; Structure-Activity Relationship | 2020 |
Novel 1,3,4-thiadiazole compounds as potential MAO-A inhibitors - design, synthesis, biological evaluation and molecular modelling.
Topics: | 2020 |
Differences in CSF Biomarkers Profile of Patients with Parkinson's Disease Treated with MAO-B Inhibitors in Add-On.
Topics: Biomarkers; Humans; Lactates; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 2022 |
Safety comparisons among monoamine oxidase inhibitors against Parkinson's disease using FDA adverse event reporting system.
Topics: Amphetamines; Dopamine Agents; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Retrospective Studies; Selegiline | 2023 |